Loading data…
Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.
$26.55M net income for the year ended January 31, 2026. These are reported results, not a forecast or a stock recommendation.
Latest-filed standard financial facts · USD
Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.
Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.
| Reported period | Reported value | Filed | Source |
|---|---|---|---|
| February 1, 2025 – January 31, 2026 | $671,310,000 | March 19, 2026 | 10-K ↗ |
| February 1, 2024 – January 31, 2025 | $653,378,000 | March 19, 2026 | 10-K ↗ |
| February 1, 2023 – January 31, 2024 | $664,389,000 | March 19, 2026 | 10-K ↗ |
| February 1, 2022 – January 31, 2023 | $744,209,000 | April 16, 2025 | 10-K ↗ |
| February 1, 2021 – January 31, 2022 | $732,393,000 | March 26, 2024 | 10-K ↗ |
| February 1, 2020 – January 31, 2021 | $506,397,000 | March 23, 2023 | 10-K ↗ |
| February 1, 2019 – January 31, 2020 | $700,966,000 | March 24, 2022 | 10-K ↗ |
| February 1, 2018 – January 31, 2019 | $679,567,000 | March 25, 2021 | 10-K ↗ |
One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.
Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 13, 2026
Response SHA-256: ea25424c037e9751d330d53e2271cfad5a9d3abab14d38acb6ddf326c8c04a9f
Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.